Published on November 25, 2009 at 10:56 AM
Unilife Medical Solutions Limited ("Unilife" or "the Company") (ASX: UNI) (PINKSHEETS: UNIFF) today announced the filing of patent applications in the United States ("US") for a new ready-to-fill syringe product to be marketed as the Unifill™ Select. Unilife is confident that this new pipeline product, which is to be primarily targeted for use with vaccines, can further expand the Company's ability to penetrate the pharmaceutical market for prefilled syringes. Unilife has recently commenced discussions with a number of interested pharmaceutical parties regarding the Unifill™ Select.
Virtually all injectable drugs and vaccines known to Unilife that are available for use in a prefilled syringe format are either indicated for administration by subcutaneous (beneath the skin) or intramuscular ("IM" -- into the muscle) injection.
The Unifill™ Select is a new product line that will complement the Unifill™ syringe which Unilife is currently bringing to market with its major pharmaceutical customer. The Unifill™ syringe features a fixed-length retractable needle, and is primarily targeted for use with drugs such as anti-coagulants, multiple sclerosis and some vaccines where prefilled syringes with a standard fixed-length needle are used to administer a dose via subcutaneous injection.
SOURCE: Unilife Medical Solutions